Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 89.9%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 37,600 shares, a growth of 89.9% from the January 31st total of 19,800 shares. Based on an average daily trading volume, of 69,500 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the shares of the company are sold short.

SOPHiA GENETICS Price Performance

NASDAQ SOPH traded up $0.07 on Friday, reaching $3.67. 27,120 shares of the company’s stock traded hands, compared to its average volume of 99,662. The stock has a market cap of $239.93 million, a PE ratio of -3.37 and a beta of 1.03. SOPHiA GENETICS has a 12 month low of $2.70 and a 12 month high of $7.37. The stock has a 50-day simple moving average of $3.57 and a 200 day simple moving average of $3.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC raised its holdings in SOPHiA GENETICS by 6.5% during the 4th quarter. Millennium Management LLC now owns 698,634 shares of the company’s stock valued at $2,180,000 after buying an additional 42,689 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in SOPHiA GENETICS by 23.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company’s stock worth $68,000 after buying an additional 4,115 shares in the last quarter. Federated Hermes Inc. raised its stake in SOPHiA GENETICS by 40.5% during the 4th quarter. Federated Hermes Inc. now owns 100,000 shares of the company’s stock valued at $312,000 after buying an additional 28,819 shares during the last quarter. Silverberg Bernstein Capital Management LLC purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth approximately $70,000. Finally, Green Alpha Advisors LLC grew its holdings in SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after purchasing an additional 25,686 shares during the period. Institutional investors own 31.59% of the company’s stock.

Analyst Ratings Changes

Separately, Craig Hallum initiated coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a “buy” rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.